XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

SEGMENT INFORMATION | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
SEGMENT INFORMATION | NOTE 11 – SEGMENT INFORMATION Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented by operating segment in making operating decisions, allocating resources, and evaluating financial performance. The Company conducted the business through two primary operating segments: NanoVibronix and ENvue. NanoVibronix derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes. Non-allocated administrative and other expenses are reflected in Corporate. The Company’s chief executive officer is its chief operating decision maker (CODM), who allocates resources to and assesses the performance of each operating segment using information about the operating segment’s loss from operations. SCHEDULE OF SEGMENT INFORMATION Goodwill and Assets
|  | NanoVibronix |  |  | ENvue |  |  | Corporate |  |  | Total |
As of June 30, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  | - |  |  |  | 38,631 |  |  |  | - |  |  |  | 38,631 |
Assets |  | $ | 2,411 |  |  | $ | 49,071 |  |  | $ | - |  |  | $ | 51,482 |
As of December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Assets |  | $ | 3,629 |  |  | $ | - |  |  | $ | - |  |  | $ | 3,629 |
Segment operating results
Six months ended June 30, 2025: |  | NanoVibronix |  |  | ENvue |  |  | Corporate |  |  | Total |
Revenues |  | $ | 1,367 |  |  | $ | 152 |  |  | $ | - |  |  | $ | 1,519 |
Cost of revenues |  |  | 875 |  |  |  | 310 |  |  |  | - |  |  |  | 1,185 |
Research and development |  |  | 1,184 |  |  |  | 318 |  |  |  | - |  |  |  | 1,502 |
Selling and marketing |  |  | 325 |  |  |  | 741 |  |  |  | - |  |  |  | 1,066 |
General and administrative |  |  | 1,231 |  |  |  | 802 |  |  |  | 1,561 |  |  |  | 3,594 |
Loss from operations |  |  | (2,248 | ) |  |  | (2,019 | ) |  |  | (1,561 | ) |  |  | (5,828 | )
Six months ended June 30, 2024: |  | NanoVibronix |  |  | ENvue |  |  | Corporate |  |  | Total |
Revenues |  | $ | 1,738 |  |  | $ | - |  |  | $ | - |  |  | $ | 1,738 |
Cost of revenues |  |  | 646 |  |  |  | - |  |  |  | - |  |  |  | 646 |
Research and development |  |  | 308 |  |  |  | - |  |  |  | - |  |  |  | 308 |
Selling and marketing |  |  | 364 |  |  |  | - |  |  |  | - |  |  |  | 364 |
General and administrative |  |  | 1,662 |  |  |  | - |  |  |  | - |  |  |  | 1,662 |
Loss from operations |  |  | (1,242 | ) |  |  | - |  |  |  | - |  |  |  | (1,242 | )
Three months ended June 30, 2025: |  | NanoVibronix |  |  | ENvue |  |  | Corporate |  |  | Total |
Revenues |  | $ | 445 |  |  | $ | 49 |  |  | $ | - |  |  | $ | 494 |
Cost of revenues |  |  | 295 |  |  |  | 234 |  |  |  | - |  |  |  | 529 |
Research and development |  |  | 772 |  |  |  | 200 |  |  |  | - |  |  |  | 972 |
Selling and marketing |  |  | 180 |  |  |  | 537 |  |  |  | - |  |  |  | 717 |
General and administrative |  |  | 807 |  |  |  | 610 |  |  |  | 835 |  |  |  | 2,252 |
Loss from operations |  |  | (1,609 | ) |  |  | (1,532 | ) |  |  | (835 | ) |  |  | (3,976 | )
Three months ended June 30, 2024: |  | NanoVibronix |  |  | ENvue |  |  | Corporate |  |  | Total |
Revenues |  | $ | 817 |  |  | $ | - |  |  | $ | - |  |  | $ | 817 |
Cost of revenues |  |  | 389 |  |  |  | - |  |  |  | - |  |  |  | 389 |
Research and development |  |  | 187 |  |  |  | - |  |  |  | - |  |  |  | 187 |
Selling and marketing |  |  | 199 |  |  |  | - |  |  |  | - |  |  |  | 199 |
General and administrative |  |  | 716 |  |  |  | - |  |  |  | - |  |  |  | 716 |
Loss from operations |  |  | (674 | ) |  |  | - |  |  |  | - |  |  |  | (674 | )
Geographic Information and Major Customer Data The following is a summary of revenues within geographic areas: SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
United States |  | $ | 462 |  |  | $ | 794 |  |  | $ | 1,448 |  |  | $ | 1,698 |
Europe |  |  | 8 |  |  |  | - |  |  |  | 17 |  |  |  | - |
Australia/New Zealand |  |  | 20 |  |  |  | 8 |  |  |  | 39 |  |  |  | 13 |
Other |  |  | 4 |  |  |  | 15 |  |  |  | 15 |  |  |  | 27 |
Total |  | $ | 494 |  |  | $ | 817 |  |  | $ | 1,519 |  |  | $ | 1,738 |
For the three and six months ended June 30, 2025, the Company generated approximately $26 and $523, respectively, in revenue from its largest direct medical distributor, Ultra Pain Products, LLC. This represents approximately 2% and 34%, respectively, of the company’s total revenue in each of the respective periods . For both the three and six months ended June 30, 2024, the Company’s largest customer comprised approximately 52% and 41% of total revenues in each of the respective periods.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration